1. COVID 19 @ NIBIB
  2. RADx℠ Tech and ATP Programs

RADx℠ Tech and ATP Programs

The RADx Tech/ATP programs are components of the overarching RADx Initiative at NIH to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The RADx Tech/ATP innovation funnel was designed to compress the customary technology development timeline from years down to just months.  This was accomplished by employing, in parallel, expert teams to address technical, regulatory, clinical, and commercialization requirements. Launched on April 29, 2020, the RADx programs were able to validate, de-risk, scale up, manufacture, and deploy novel tests through a seamless pipeline by fall 2020.

generic bar chart titled tests produced

Program Dashboard

Learn More

Summary data on proposals submitted to the RADx℠ Tech and ATP Programs.

  • 180 million tests produced 
  • 150 companies supported
  • 16 tests with FDA authorization
RADx Tech organization chart

Partners

Learn More

The RADx Tech and ATP programs leverage the Point of Care Technology Research Network and joined with numerous other federal agencies, offices, NIH institutes, and contractors.

RADx Testing

Tests in Development

Learn More

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

Test Calculator

Learn about the COVID-19 Testing Impact Calculator, a tool to help organizations plan for and demonstrate how testing and other mitigation measures can curb the spread of the virus. The tool includes a K-12 playbook to help provide guidance for school administrators and an Implementation Guide for any organization developing a testing strategy.

Webinar Series

This webinar series hosted by POCTRN provides information on RADx Tech/ATP program activities.  Register for upcoming events or watch previous webinars.

Videos

View videos about RADx Tech/ATP programs, interviews with the NIBIB Director and more.

COVID-19 Test Us

Information about studies to evaluate diagnostic tests being developed for COVID-19.

Using an ipad

Program Contacts

Current grantees contact Program Director on your existing award.

RADx℠ Tech programmatic or technical inquiries: info.radx@poctrn.org

All other RADx℠ Tech Applicants: RADxNIBIB@mail.nih.gov 

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov 

All others: COVID19NIBIB@nibib.gov 

Related Resources

FAQs about the RADx Tech Program

Info on all RADx Programs

Media Inquiries: 
nibibpress@mail.nih.gov 
or 301-496-3500

Related News

View All News
CDC and NIH bring COVID-19 self-testing to residents in two locales
Press Releases
March 31, 2021
woman looking at home covid19 test
The CDC, in collaboration with the NIH, has launched an innovative community health initiative called “Say Yes! COVID Test.” Up to 160,000 residents in two US communities will have access to free, rapid antigen tests that they can administer themselves to use three times a week for one month.
RADx diversifies COVID-19 test portfolio with four new contracts, including one to detect variants
Science Highlights
March 23, 2021
COVID19 testing technology with digital health app for smartphone
NIH has awarded four additional contracts for the development and scaled-up manufacturing of new COVID-19 diagnostic testing technologies through its Rapid Acceleration of Diagnostics Tech (RADx) initiative. The awards total $29.3 million and will help increase testing capacity for COVID-19.
NIH to evaluate COVID-19 at-home testing system
Press Releases
March 1, 2021
diagnostic test in a box
An NIH-funded research team has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home COVID-19 Test, which received FDA emergency use authorization for use with a prescription.
RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing
NIBIB in the News
February 17, 2021
The final RADx portfolio of products to be developed and scaled includes a diversity of diagnostics from companies such as Illumina, Quidel, Fluidigm, and Mesa Biotech, and is likely to result in a near-term manufacturing boom in rapid antigen tests and over-the-counter home-use diagnostics. Source: genomeweb.
NIH’s RADx Tech program inks additional contracts for COVID-19 diagnostic tests and supplies
Science Highlights
January 12, 2021
COVID19 testing nasal swabs
The National Institutes of Health has awarded three new contracts totaling $36.7 million for the development of new COVID-19 diagnostic testing technologies and production of specimen collection kits and swabs. The Rapid Acceleration of Diagnostics (RADx) initiative has advanced the scale-up of 25 testing projects since July 2020, which now include lab-based, point-of-care, and potential at-home formats.